Marie- Andrée Gamache appointed Country President, Novartis Innovative Medicines, UK & Ireland
Jun 01, 2022
Novartis UK is announcing that Marie-Andrée Gamache has been appointed to the role of Country President, Novartis Innovative Medicines UK and Ireland.
Marie-Andrée will move to the Novartis UK organisation having spent over 20 years in a wide range of leadership roles at country, regional and global levels, across Europe, North America and Emerging Markets. Throughout her career her priorities have seen her focus on helping create the right environment for better access to innovative medicines for patients whilst also developing teams and company culture.
Marie-Andrée will return to the UK from the United Arab Emirates, where since 2019 she has served as Head of Middle East and Africa, Novartis Oncology. She originally joined Novartis in 2004 in the pharmaceutical division where she held a variety of roles in Sales and Brand Management, including in the UK. Marie-Andrée then served as Hematology Franchise Head, Belgium and Luxembourg, for three years. In 2015, she gained General Manager experience at Merck Serono both at a country and regional level, before returning to Novartis in 2019. In total, she has spent nearly 14 years with Novartis.
As Country President of Novartis UK and Ireland, Marie-Andrée will focus on creating an organisation with enhanced patient and customer focus to build bold partnerships with the NHS; improving access to treatments for patients and supporting the healthcare systems to build back better post-pandemic.
Commenting on her new role, Marie-Andrée said: “I am hugely looking forward to returning to the UK and building on the strong foundations already laid by the Novartis UK & Ireland teams. As the NHS recovers from Covid and looks to address the backlog, I know the innovation of Novartis can contribute to better access to medicines for patients. Our challenge now is to build on our role as a trusted and innovative partner for the UK and Ireland’s health systems. I believe our potential to help improve patient lives is huge and I am delighted to be able to work with the UK team, the NHS and Government, academia and our trade associations to ensure we secure vibrant life sciences industries across the UK and Ireland.”